Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A
Our study reveals the key roles of ASB3 in the development of MASLD and suggests a novel therapeutic potential for MASLD.
Authors
- Lanxin Wang (ORCID: https://orcid.org/0009-0009-6967-7400)
- Yuli Lin (ORCID: https://orcid.org/0000-0002-8779-2471)
- Dongqin Yang (ORCID: https://orcid.org/0000-0003-0126-5898)
- Wulei Hou
- Mengxiao Ge (ORCID: https://orcid.org/0000-0002-2333-2572)
- Ming Guan (ORCID: https://orcid.org/0000-0002-8796-2653)
- Haoye Liu (ORCID: https://orcid.org/0000-0003-2139-3598)
- Chunhua Song (ORCID: https://orcid.org/0000-0002-4081-2543)
- Xiyu Deng
- Zuoyun Wang (ORCID: https://orcid.org/0000-0003-4428-5477)
- Wenli Zhang (ORCID: https://orcid.org/0000-0001-8304-0638)
- Linlin Huang (ORCID: https://orcid.org/0000-0003-0317-4893)
- Zhihao Wu (ORCID: https://orcid.org/0000-0001-8099-6693)
Institutions
- Shanghai Medical College of Fudan University (CN)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- The Ohio State University Wexner Medical Center (US)
- Huashan Hospital (CN)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2025-08-08
- DOI
- https://doi.org/10.3350/cmh.2024.1041
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00